ATE547104T1 - Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungen - Google Patents

Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungen

Info

Publication number
ATE547104T1
ATE547104T1 AT04741805T AT04741805T ATE547104T1 AT E547104 T1 ATE547104 T1 AT E547104T1 AT 04741805 T AT04741805 T AT 04741805T AT 04741805 T AT04741805 T AT 04741805T AT E547104 T1 ATE547104 T1 AT E547104T1
Authority
AT
Austria
Prior art keywords
lung
treatment
sildenafil
composition containing
surfactant
Prior art date
Application number
AT04741805T
Other languages
English (en)
Inventor
Stefan-Lutz Wollin
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Application granted granted Critical
Publication of ATE547104T1 publication Critical patent/ATE547104T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT04741805T 2003-06-16 2004-06-15 Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungen ATE547104T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03013615 2003-06-16
PCT/EP2004/051120 WO2004110450A1 (en) 2003-06-16 2004-06-15 Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases

Publications (1)

Publication Number Publication Date
ATE547104T1 true ATE547104T1 (de) 2012-03-15

Family

ID=33547593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04741805T ATE547104T1 (de) 2003-06-16 2004-06-15 Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungen

Country Status (7)

Country Link
US (1) US7238664B2 (de)
EP (1) EP1638567B1 (de)
JP (1) JP2006527737A (de)
AT (1) ATE547104T1 (de)
CA (1) CA2529007C (de)
ES (1) ES2383206T3 (de)
WO (1) WO2004110450A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100891595B1 (ko) * 2005-02-28 2009-04-03 주식회사 케이티앤지 혈액 단백질의 삼출을 감소시키는 조성물
WO2006094924A2 (en) * 2005-03-09 2006-09-14 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
CA2622200A1 (en) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
WO2007097502A1 (en) * 2006-02-23 2007-08-30 Kt & G Corporation Composition for reducing the exudation of serum proteins
AU2007303846B2 (en) * 2006-10-04 2011-03-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
US20100284969A1 (en) * 2007-06-05 2010-11-11 Frank Guarnieri Methods and Compositions for Delivery of Medicaments to the Lungs
WO2010013925A2 (en) * 2008-07-31 2010-02-04 Dong-A Pharmaceutical. Co., Ltd. Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof
US9289388B2 (en) 2008-12-10 2016-03-22 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
EP3082428A4 (de) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5-inhibitorpulverformulierungen und zugehörige verfahren
US10058545B2 (en) * 2016-08-09 2018-08-28 Cipla Limited Method of treating pulmonary arterial hypertension

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4434629C1 (de) 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
DE69835594T2 (de) * 1997-02-17 2007-08-16 Altana Pharma Ag Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten
DE19827907C2 (de) 1998-06-23 2003-05-15 Altana Pharma Ag Neue pharmazeutische Zusammensetzungen zur Behandlung von IRDS und ARDS
AU1161300A (en) * 1998-11-10 2000-05-29 Byk Gulden Lomberg Chemische Fabrik Gmbh Treatment set containing lungsurfactant compositions
EP1223170B1 (de) * 1999-10-12 2005-12-28 Takeda Pharmaceutical Company Limited Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
JP2003522138A (ja) 2000-02-11 2003-07-22 アルタナ ファルマ アクチエンゲゼルシャフト 慢性肺疾患の予防および治療のための肺表面活性剤の新規使用
US20030158087A1 (en) * 2000-04-12 2003-08-21 Dietrich Hafner Novel use of fulmonary surfactant for the prophylaxis or early treatment if acute fulmonary diseases
JP2005500349A (ja) 2001-08-01 2005-01-06 アルタナ　ファルマ　アクチエンゲゼルシャフト 呼吸症候群のための選択的ｃｏｘ−２インヒビターと肺表面活性物質の組合せ物

Also Published As

Publication number Publication date
CA2529007C (en) 2012-03-27
ES2383206T3 (es) 2012-06-19
JP2006527737A (ja) 2006-12-07
US20060148693A1 (en) 2006-07-06
EP1638567B1 (de) 2012-02-29
EP1638567A1 (de) 2006-03-29
US7238664B2 (en) 2007-07-03
WO2004110450A1 (en) 2004-12-23
CA2529007A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
NO20055941L (no) Anvendelse av en sammensetning omfattende en PDE4-inhibitor og en PDE5-inhibitor
NO2007010I2 (no) Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt
CY1108146T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ
DE60330485D1 (de) Zur behandlung von diabetes
EP1673078A4 (de) Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit
ATE547104T1 (de) Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungen
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
IS7817A (is) Fenýlalanín afleiður sem dípeptidýl peptíðasa hindrar til að meðhöndla eða fyrirbyggja sykursýki.
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE417832T1 (de) Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
EP1841426A4 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
RS51631B (en) 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS β-SECRETASE INHIBITORS (BACE)
ZA200710379B (en) Pyrrolopyridines useful as inhibitors of protein kinase
UY28958A1 (es) Nuevos derivados de piridazin-3(2h)-ona
TNSN04165A1 (en) Substituted hydroxyethylamines
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
EP1689713A4 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE457736T1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
HUP0401614A2 (hu) PDE4 inhibitort és antikolinerg hatóanyagot tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
RS51519B (en) HYINAZOLINE DERIVATIVES USEFUL FOR TREATMENT OF PERIPHERAL ARTERIAL DISEASES AND AS PHOSPHODIESTERASE INHIBITORS
HUP0204097A2 (hu) Guanozin-3',5'-monofoszfát-foszfodiészteráz inhibitorok alkalmazása diabetikus fekélyek kezelésére szolgáló készítmények előállítására
NO20033541L (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer